Skip to main content
Fig. 6 | The Journal of Headache and Pain

Fig. 6

From: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Fig. 6

Change in A) HIT-6 and B) MIDAS scores in participants aged ≥60 years and overall population. HIT-6, 6-item Headache Impact Test; MIDAS, Migraine Disability Assessment; LSM, least-squares mean; LSMD, least-squares mean difference; SE, standard error. Data shown are the LSM changes from baseline in HIT-6 and MIDAS scores during 12 weeks of double-blind treatment. aP = 0.0005 vs placebo. bP < 0.0001 vs placebo. cP < 0.01 vs placebo

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us